ARCA biopharma, Inc.
NASDAQ:ABIO
2.4 (USD) • At close August 30, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | ARCA biopharma, Inc. |
Symbool | ABIO |
Munteenheid | USD |
Prijs | 28.8 |
Beurswaarde | 34,817,184 |
Dividendpercentage | 0% |
52-weken bereik | 2.247 - 53.88 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Michael R. Bristow M.D., Ph.D. |
Website | https://www.arcabio.com |
An error occurred while fetching data.
Over ARCA biopharma, Inc.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)